Guggenheim Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $1100
Benzinga Newsdesk 1 hour ago
Analyst RatingsNewsPrice TargetHot
Guggenheim analyst Yatin Suneja maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $1030 to $1100.
Guggenheim analyst Yatin Suneja maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $1030 to $1100.